Arvee Laboratories (Small Cap - Potential Multibagger) Share Target 2025, 2026 To 2035
|
Arvee Laboratories |
|||
|
Price: ₹145.10 (+4.33%) | ||
| 52 Week Low: ₹117.05 52 Week High: ₹315.00 |
|||
| Market Capital: 179.55 Crore (Smallcap) | |||
| Basic Materials -> Specialty Chemicals | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Arvee Laboratories Share Price Target For 2025
- 1.1.1: Arvee Laboratories Share Price Target Table For 2025
- 1.1.2: Short-Term Technical Outlook
- 1.2: Arvee Laboratories Share Price Target For 2026
- 1.2.1: Arvee Laboratories Share Price Target Table For 2026
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Arvee Laboratories Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
- 3: Arvee Laboratories Brief Company Overview
- 4: Arvee Laboratories Financial Performance
- 4.0.1: Is Arvee Laboratories A Good Buy For Long Term?
Arvee Laboratories, a Small Cap company in the Specialty Chemicals Industry has delivered 442.4% returns in 5-year showing 39.6% quarterly revenue growth with 4.5% profit margin, making it a potential Multibagger.
To predict the Arvee Laboratories's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Arvee Laboratories Share Price Target For 2025
The line chart displays the monthly closing prices of Arvee Laboratories with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Arvee Laboratories shares in 2025, see the table below.
Arvee Laboratories Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 165.56 (+14.1%) | Price Action: 04 Nov 2024 Low |
| 2025 Target 2 | 163.57 (+12.72%) | Price Action: 13 Jan 2025 High |
| 2025 Target 1 | 161.87 (+11.55%) | Price Action: 23 Jan 2025 High |
| Current Price | 145.10 | Arvee Laboratories's share price as of 21 Feb 2025 |
| Stop Loss 1 | 137.6 (-5.17%) | Price Action: Apr 2024 Low |
| Stop Loss 2 | 136.2 (-6.14%) | Price Action: 19 Mar 2024 High |
| Stop Loss 3 | 134.35 (-7.41%) | Price Action: 13 Mar 2024 Low |
Short-Term Technical Outlook
Current Technical Position: Arvee Laboratories is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹148.4 serves as the nearest technical reference point.
Historical Returns: 3-month: -9.88% | 6-month: -20.44% | 1-year: +4.38%
Arvee Laboratories Share Price Target For 2026
The line chart displays the monthly closing prices of Arvee Laboratories with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Arvee Laboratories shares in 2026, see the table below.
Arvee Laboratories Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 285.87 (+97.01%) | Fibonacci Extension Level 64.90% |
| 2026 Target 2 | 279.62 (+92.7%) | Price Action: Chart |
| 2026 Target 1 | 276.85 (+90.79%) | Price Action: 15 Apr 2024 High |
| Current Price | 145.10 | Arvee Laboratories's share price as of 21 Feb 2025 |
| Stop Loss 1 | 111.0 (-23.51%) | Price Action: 22 Nov 2023 Low |
| Stop Loss 2 | 109.89 (-24.27%) | Price Action: Chart |
| Stop Loss 3 | 107.91 (-25.64%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: Arvee Laboratories is currently trading near its 52-week low of ₹117.05, indicating potential value opportunity.
Long-Term Trend Analysis: The stock is in a bearish long-term trend, trading below key long-term moving averages.
Long-Term Performance: 1-year: +4.38% | 3-year: +85.31% | 5-year: +442.43%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Arvee Laboratories Share Price Target Chart and Table From 2025, 2026, 2027 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹145.10 | ||
| 2025 | ₹284.64 | +96.16% | ₹288.91 |
| 2026 | ₹405.98 | +42.62% | ₹412.07 |
| 2027 | ₹608.72 | +49.93% | ₹617.85 |
| 2028 | ₹848.59 | +39.4% | ₹861.32 |
| 2029 | ₹1,057.65 | +24.63% | ₹1,073.51 |
| 2030 | ₹1,334.88 | +26.21% | ₹1,354.90 |
| 2031 | ₹1,792.76 | +34.3% | ₹1,819.65 |
| 2032 | ₹2,478.43 | +38.24% | ₹2,515.61 |
| 2033 | ₹3,148.19 | +27.02% | ₹3,195.41 |
| 2034 | ₹3,991.28 | +26.78% | ₹4,051.15 |
| 2035 | ₹4,947.93 | +23.96% | ₹5,022.15 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Arvee Laboratories Brief Company Overview
Arvee Laboratories: A Leader in Specialty Chemicals Overview Established in 2012, Arvee Laboratories (India) Ltd. is a renowned manufacturer of specialized chemicals, serving both domestic and international markets. Headquartered in Ahmedabad, India, the company has...
gained prominence for its commitment to innovation and diverse product portfolio. Products Polymer Modifiers: Including dimethyl 5-sodiosulfoisophthalate and 5-sodiosulfo-bis-(ß-hydroxyethyl)-isophthalate Contrast Media Intermediates: Such as 5-nitroisophthalic acid and 5-aminoisophthalic acid Drug Intermediates: Comprising 2-acetyl thiophene and 4–amino pyridine Reputation Arvee Laboratories has carved a niche for itself in the industry, known for its consistent delivery of high-quality products and exceptional customer service. Commitment The company is deeply committed to environmental sustainability and ethical practices, ensuring its operations adhere to the highest standards.Arvee Laboratories Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 179.55 Crore | Market valuation of Arvee Laboratories's shares. |
| Revenue (TTM) | 33.35 Crore | Total revenue generated by Arvee Laboratories over the past twelve months. |
| Net Income (TTM) | +1.5 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +11.6% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +4.51% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+39.6% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+93.3% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
3.43 | Company's total debt divided by total shareholder equity. |
| Total Debt | 1 Crore | Sum of Arvee Laboratories's current & long-term financial obligations. |
| Total Cash | 7.54 Crore | Total amount of liquid funds available to Arvee Laboratories. |
| Beta | 0.52 | Beta is less than 1 indicating that the Arvee Laboratories's price is less volatile than the market. |
Is Arvee Laboratories A Good Buy For Long Term?
Arvee Laboratories, a small-cap stock with a market capitalization of ₹179.55 crore, presents a mixed picture for long-term investors. While its five-year return of 499.76% is impressive, recent performance shows a decline: -17.11% over the past three months and -10.71% YTD. The Q1 2024-25 report reveals a modest net profit of ₹1.5 crore (4.51% profit margin) on ₹33.35 crore revenue, along with a manageable debt of ₹1 crore and healthy cash reserves of ₹7.54 crore. Considering the volatility and recent negative trends, Arvee Laboratories is an average buy for long-term investment, requiring close monitoring.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
